ArticleCancer biomarkers : section A of Disease markers2019
Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- TCF4 as a potential prognostic biomarker and an anticancer target in gastric cancer.Translational cancer research · 2024Article
- Article
- Identification of potential biomarkers for papillary thyroid carcinoma by comprehensive bioinformatics analysis.Molecular and cellular biochemistry · 2023Article
- miR-20a/TCF4 axis-mediated inhibition of hepatocytes proliferation impairs liver regeneration in mice PHx model by regulating CDC2 and CDC6.Journal of cellular and molecular medicine · 2021Article
- Co-Overexpression of GRK5/ACTC1 Correlates With the Clinical Parameters and Poor Prognosis of Epithelial Ovarian Cancer.Frontiers in molecular biosciences · 2021Article
- FOXD3-induced miR-133a blocks progression and metastasis of colorectal cancer through regulating UBA2.Journal of Cancer · 2021Article
- miR-326 inhibits the cell proliferation and cancer stem cell-like property of cervical cancerAnnals of translational medicine · 2020Article
- LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.Oncology letters · 2019Article
- Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer.Cancer biomarkers : section A of Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate TCF4 expression in epithelial ovarian cancer, and to explore its correlation with clinicopathological parameters and clinical prognosis of epithelial ovarian cancer.
methodsFrom 2009 to 2017, 188 cases of paraffin-embedded epithelial ovarian cancer tissues and 41 paratumor ovarian tissues which had been confirmed at the memorial hospital of Sun Yat-sen University were collected in this study, and the expression of TCF4 was performed by immunohistochemistry using a polyclonal antibody specific for TCF4.
resultsThe expression of TCF4 protein was associated with disease progression free survival and overall survival in epithelial ovarian cancer patients; and TCF4 overexpression was associated with age, FIGO stage, lymph node metastasis, intraperitoneal metastasis, intestinal metastasis, vital status, intraperitoneal recurrence, and serum CA153. Moreover, in a multivariate Cox regression analysis TCF4 overexpression was an indeed independent prognostic factor in epithelial ovarian cancer.
conclusionsTCF4 may play an oncogenic role in epithelial ovarian cancer, and TCF4 is a useful independent prognostic biomarker of epithelial ovarian cancer, and it may provide a candidate target therapy treatment in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.